Table 3.

PAH studies reporting effect of bosentan

First author	Name	Year	N=	Groups	Comparator	Design	Effect vs comparator	P-value
Channick28	Study 351	2001	32	IPAH; SSc	Placebo	DB R	6MWD +76 m	p < 0.05
Rubin29	BREATHE-1	2002	213	IPAH; CTD	Placebo	DB R	6MWD +35 m (250 mg)	p < 0.01
Barst13	BREATHE-3	2003	19		Baseline	OL	mPAP −8 mmHg PVR –300 dynes/s/cm5
Humbert30	BREATHE-2	2004	33	IPAH; CTD	Placebo	R	PVR −188 dynes/s/cm5	ns
Sitbon12	BREATHE-4	2004	16	HIV	Baseline	OL	6MWD +91 m	p < 0.001
Wilkins31	SERAPH	2005	26	IPAH; CTD	Sildenafil	R	6MWD −16 m	ns
Barst32	STRIDE-2	2006	185	IPAH; CTD; CHD	Sitaxentan	OL R	6MWD +1.5 m	ns
Galiè14	BREATHE-5	2006	54	CHD	Placebo	DB R	PVRI −472 dynes/s/cm5	p < 0.05
							6MWD +53 m	p < 0.01
Mathai33		2006	25	IPAH; SSc	Baseline	OL	6MWD +52 m	ns
Denton34	TRUST	2007	53	CTD	Baseline	OL	12 patients improved FC
Akagi35		2008	8	IPAH	Baseline	OL	mPAP −13 mmHg	p < 0.05
Galiè36	EARLY	2008	185	IPAH; CHD; CTD; HIV	Placebo	DB R	6MWD +19 m	ns
							PVR −197 dynes/s/cm5	p < 0.0001
Jaïs15	BENEFIT	2008	99	CTEPH	Placebo	DB R	PVR −193 dynes/s/cm5	p < 0.0001
							6MWD +2 m	ns

Abbreviations: IPAH, idiopathic pulmonary artery hypertension; SSc, scleroderma-associated pulmonary arterial hypertension; CTD, connective tissue disease associatedi pulmonary artery hypertension; HIV, human immunodeficiency virus associated pulmonary artery hypertension; CHD, congenital heart disease associated pulmonary artery hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; DB, double blinded; R, randomized; OL, open label, 6MWD, six-minute walk distance; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; FC, functional class.